Division of Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands.
J Hypertens. 2010 May;28(5):1044-53. doi: 10.1097/HJH.0b013e328335c381.
To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma.
Both corticosterone and aldosterone increased left ventricular pressure in the rat heart. Aldosterone decreased coronary flow, whereas corticosterone increased it. All corticosterone effects were blocked by the glucocorticoid receptor antagonist, RU486, and unaltered by the mineralocorticoid receptor antagonist, canrenoate, or the 11beta-hydroxysteroid dehydrogenase (HSD11B)2 inhibitor, carbenoxolone. Unlike mineralocorticoid receptor blockade, RU486 did not ameliorate postischemia infarct size and arrhythmias. Corticosterone, when added to the perfusion buffer, rapidly accumulated at cardiac tissue sites, reaching steady-state levels that were identical to those in coronary effluent, independently of the presence of aldosterone, RU486 or canrenoate. After stopping the perfusion, cardiac corticosterone fully washed away with a half-life of less than 1 min. Measurements of steroid-synthesizing enzyme gene expression levels in human ventricular and atrial tissue pieces from heart-beating organ donors, patients with end-stage heart failure and hypertrophic cardiomyopathy patients revealed that under no condition, the human heart was capable of synthesizing aldosterone or cortisol de novo. Yet, expression of HSD11B1, HSD11B2, mineralocorticoid receptors and glucocorticoid receptors was found, and HSD11B2 and mineralocorticoid receptors were upregulated in pathological conditions. Moreover, aldosterone reduced cardiac inotropy in a Na/K/2Cl cotransporter-dependent manner.
Both cortisol/corticosterone and aldosterone accumulate in the cardiac interstitium. The presence of HSD11B2 and mineralocorticoid receptors/glucocorticoid receptors at cardiac tissue sites allows both steroids to exert their effects via separate mechanisms.
为了测试糖皮质激素是否作为心脏盐皮质激素受体的内源性激动剂,我们评估了醛固酮和皮质酮的心脏效应以及与类固醇从血浆摄取相比的心脏类固醇生成作用。
皮质酮和醛固酮均增加了大鼠心脏的左心室压力。醛固酮降低了冠脉流量,而皮质酮增加了冠脉流量。所有皮质酮的作用均被糖皮质激素受体拮抗剂 RU486 阻断,而不受盐皮质激素受体拮抗剂坎利酮或 11β-羟类固醇脱氢酶(HSD11B)2 抑制剂 carbenoxolone 的影响。与盐皮质激素受体阻断不同,RU486 并未改善缺血后梗死面积和心律失常。当皮质酮添加到灌注缓冲液中时,它会迅速在心脏组织部位积聚,达到与冠脉流出液相同的稳态水平,而与醛固酮、RU486 或坎利酮的存在无关。停止灌注后,心脏皮质酮的半衰期不到 1 分钟,即可完全洗脱。对来自心跳器官捐献者、终末期心力衰竭患者和肥厚型心肌病患者的人心室和心房组织块中的类固醇合成酶基因表达水平的测量表明,在任何情况下,人体心脏都不能从头合成醛固酮或皮质醇。然而,发现了 HSD11B1、HSD11B2、盐皮质激素受体和糖皮质激素受体的表达,并且在病理条件下 HSD11B2 和盐皮质激素受体上调。此外,醛固酮以 Na/K/2Cl 共转运蛋白依赖性方式降低了心脏的变力作用。
皮质醇/皮质酮和醛固酮均在心脏间质中积聚。HSD11B2 和盐皮质激素受体/糖皮质激素受体在心脏组织部位的存在允许两种类固醇通过独立的机制发挥作用。